Welcome to today's Medical News Today News Alert containing today's medical news headlines for your chosen categories. You will only receive these alerts when new news is available for your chosen categories.
To unsubscribe from our news alerts, or to alter any of your subscription details (name,e-mail address etc) please see
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
----------------------------------------------
** BREAST CANCER News **
Professor Jan Vermorken Is The New Editor-in-chief Of Annals Of Oncology
http://www.medicalnewstoday.com/articles/132162.php
Professor Jan B. Vermorken, an internationally respected medical oncologist based at Antwerp University Hospital (Edegem, Belgium), has been appointed to be the next editor-in-chief of the cancer journal, <i>Annals of Oncology</i>.
First International Conference On Inflammatory Breast Cancer
http://www.medicalnewstoday.com/articles/132115.php
The University of Texas M. D. Anderson Cancer Center held the first international inflammatory breast cancer (IBC) conference on December 6-7, to bring together internationally recognized breast cancer clinicians and scientists.
U.K. Geneticists Concerned Patent Ruling On Breast Cancer Gene Test Could Stifle Innovation
http://www.medicalnewstoday.com/articles/132069.php
A recent ruling by the <A href="http://www.epo.org/" target=_new>European Patent Office</A> could make it more difficult and costly for health care providers in the United Kingdom to test for the BRCA1 genetic mutation, which can increase a woman's risk for breast cancer, London's <A href="http://www.
----------------------------------------------
** CANCER / ONCOLOGY News **
Precious Metal, Osmium, Could Lead To Next Generation Of Cancer Treatments
http://www.medicalnewstoday.com/articles/132175.php
A precious metal which has never before been used in a clinical setting is being developed as an anti-cancer agent by Warwick researchers. The metal, osmium, is closely related to platinum, which is widely used to treat cancers in the form of the drug cisplatin.
Professor Jan Vermorken Is The New Editor-in-chief Of Annals Of Oncology
http://www.medicalnewstoday.com/articles/132162.php
Professor Jan B. Vermorken, an internationally respected medical oncologist based at Antwerp University Hospital (Edegem, Belgium), has been appointed to be the next editor-in-chief of the cancer journal, <i>Annals of Oncology</i>.
Supposed Help Against Tumors - How Glioblastoma Tumor Cells Use The Body's Protection
http://www.medicalnewstoday.com/articles/132136.php
Glioblastoma is one of the most common but also most aggressive brain tumors, almost invariably leading to death in a short time. It consists of different cell types and their precursors, complicating successful treatment.
Cancer Specialists Struggle With Giving Patients Bad News And Discussing High Cost Drugs
http://www.medicalnewstoday.com/articles/132131.php
Oncologists need more guidance to help them talk to their patients about difficult topics such as the cost of medication and treatment failure, according to a study published the latest issue of the <a href="http://www.
American Society Of Hematology Annual Meeting Late-Breaking Data
http://www.medicalnewstoday.com/articles/132121.php
Four studies highlighting late-breaking research advances in the treatment of cancer and sickle cell disease were presented at the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA.
Study Shows Racial, Economic Disparities In Head, Neck Cancer Survival Rates
http://www.medicalnewstoday.com/articles/132100.php
Blacks and people living in poverty have lower survival rates for head and neck cancers than other groups, according to a report published recently in the journal <cite>Cancer</cite>, <a href="http://www.
----------------------------------------------
** CERVICAL CANCER / HPV VACCINE News **
No news for this category today.
----------------------------------------------
** COLORECTAL CANCER News **
No news for this category today.
----------------------------------------------
** LUNG CANCER News **
No news for this category today.
----------------------------------------------
** LYMPHOMA / LEUKEMIA News **
Adding Rituximab (MabThera) To Chemotherapy Almost Doubles Complete Remission For People With Chronic Lymphocytic Leukaemia (CLL)
http://www.medicalnewstoday.com/articles/132177.php
Impressive new data presented today from two landmark studies show that a new 'immunochemotherapy' treatment combination allows people with the most common form of leukaemia(1,2,3) to almost double their chance of achieving a complete remission*, compared to those treated with chemotherapy alone(4,5).
Seattle Genetics Reports Durable Objective Responses With SGN-35 In Lymphoma - American Society Of Hematology 50th Annual Meeting
http://www.medicalnewstoday.com/articles/132159.php
Seattle Genetics, Inc. (Nasdaq: SGEN) today reported data from a phase I clinical trial of SGN-35, an antibody-drug conjugate (ADC), demonstrating multiple complete and partial responses at well-tolerated doses in patients with relapsed or refractory Hodgkin lymphoma and other CD30-positive hematologic malignancies.
Rituxan In Combination With Chemotherapy Improves Progression-Free Survival In Difficult-to-Treat Form Of Blood Cancer
http://www.medicalnewstoday.com/articles/132157.php
Genentech, Inc. (NYSE:DNA) and Biogen Idec (Nasdaq:BIIB) today announced that two global Phase III studies in chronic lymphocytic leukemia (CLL), CLL8 and REACH, showed Rituxan® (rituximab) plus chemotherapy significantly increased the time patients lived without their disease advancing, as defined by the primary endpoint of progression-free survival (PFS), when compared to chemotherapy alone.
Hairy-Cell Leukemia: 50 Years Of Research
http://www.medicalnewstoday.com/articles/132109.php
In 1958, Ohio State University cancer researcher Dr. Bertha Bouroncle first identified a deadly disease now known as hairy-cell leukemia, a once fatal disease that can now be effectively treated.
----------------------------------------------
** PROSTATE / PROSTATE CANCER News **
European Prostate Cancer Device Market Will Be Driven By Earlier Detection Of Prostate Cancer, According To Millennium Research Group
http://www.medicalnewstoday.com/articles/132148.php
According to Millennium Research Group's (MRG's) European Markets forUrological Devices 2009 report, the prostate cancer device market-comprisingbrachytherapy seeds, cryotherapy, and high-intensity focused ultrasound(HIFU) devices-will be driven by earlier detection of prostate cancer due toan increase in screening over the next five years.
Reduced Muscle Strength And Functional Performance In Men With Prostate Cancer Undergoing Androgen Suppression: Cross-Sectional Investigation
http://www.medicalnewstoday.com/articles/132142.php
UroToday.com - It is becoming clearer that androgen suppression therapy (AST) is associated with undesirable side effects.<sup>1</sup> While the decline in bone and lean mass following AST has been consistently documented, <sup>2, 3</sup> only scant information exists regarding the impact of testosterone suppression on muscle strength and physical performance.
Association Study Of Prostate Cancer Susceptibility Variants With Risks Of Invasive Ovarian, Breast, And Colorectal Cancer
http://www.medicalnewstoday.com/articles/132140.php
UroToday.com - A large genome-wide association study only identifies a modest association between prostate cancer (CaP) susceptibility loci and risk of ovarian and breast cancer susceptibility.
Targeted Delivery Of Cisplatin To Prostate Cancer Cells By Aptamer Functionalized Pt(IV) Prodrug-PLGA-PEG Nanoparticles
http://www.medicalnewstoday.com/articles/132139.php
UroToday.com - In the November 11, 2008 issue of the <i>Proceedings of the National Academy of Sciences, USA</i>, Dr. Shanta Dhar and researchers from MIT and Harvard presented in vitro and in vivo data on delivery of cisplatin to prostate cancer (CaP) cells by nanoparticles (NPs).
Men With Wives, Significant Others More Likely To Be Screened For Prostate Cancer
http://www.medicalnewstoday.com/articles/132134.php
Although the link between early screening and prostate cancer survival is well established, men are less likely to go for early screening unless they have a wife or significant other living with them, according to a study published in <a href="http://cebp.
-------------------------------------------------------------
You are receiving this news alert e-mail because you subscribed via an online form on our web site. If you wish to unsubscribe, please visit
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
No comments:
Post a Comment